LMAT analyst estimates
LeMaitre Vascular (LMAT) analyst ratings, the average price target and its range, and every firm's latest call.
LMAT analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Aug 6, 2026 | Barrington | LeMaitre upgraded to Outperform from Market Perform at Barrington | $95.00 |
| May 6, 2026 | Barrington | LeMaitre price target raised to $120 from $105 at Barrington | $120.00 |
| May 6, 2026 | Lake Street | LeMaitre price target raised to $135 from $110 at Lake Street | $135.00 |
| Nov 10, 2025 | Cantor Fitzgerald | Cantor Fitzgerald Reiterates Neutral Rating on LeMaitre Vascular (LMAT) | $95.00 |
| Nov 5, 2025 | Roth Capital | LeMaitre resumed with a Buy at Roth Capital | $108.00 |
| Feb 28, 2025 | Lake Street | LeMaitre price target raised to $110 from $105 at Lake Street | $110.00 |
| Oct 15, 2024 | Cantor Fitzgerald | LeMaitre initiated with a Neutral at Cantor Fitzgerald | $96.00 |
| Aug 20, 2024 | JMP Securities | LeMaitre price target raised to $100 from $77 at JMP Securities | $100.00 |
| Apr 26, 2024 | Stifel Nicolaus | Stifel Upgrades LeMaitre Vascular (LMAT) to Buy | $75.00 |
| Sep 6, 2023 | Oppenheimer | Why LeMaitre Vascular Is A Market Leader In Core Segments: Oppenheimer Initiates With Outperform Rating | $70.00 |
- 4 firms rate LMAT: 3 buy, 1 hold, 0 sell.
- The average price target is $115.00 from 2 analysts, from $95.00 to $135.00.
Updated 2026-11-02 17:50 UTC